retatrutide clinical trials retatrutide Reta trial data & dosing — a must read (Reta) isn't just another GLP-1. It's a triple-agonist peptide studied in Phase 3 for metabolic health — targeting GLP-1, GIP Retatrutide Phase 3: TRIUMPH Program

use additional barrier methods or switch to non-oral contraception Discuss contraception thoroughly with provider before starting treatment Why Contraindicated : Animal studies showed potential fetal harm Human pregnancy data very limited Unknown whether medication passes to fetus Weight loss during pregnancy generally not recommended Q: What should I do if I experience severe side effects

Obesity is a major risk factor for cardiovascular disease, the leading cause of death in people with common arthritides such as osteoarthritis (OA), gout, rheumatoid arthritis, psoriatic arthritis and axial spondyloarthritis

Alcohol consumption can contribute to weight gain, hyperlipidemia, and elevated glucose levels

pancreatitis is a rare but noted risk in this class

Prescription GLP-1 medications directly activate GLP-1 receptors and produce weight loss in the range of 15-20%+ of body weight in clinical trials

No differences in response rate were found on post-injection days